The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • Marketing & Promotions
    • The Antibody Society’s Committees
      • Meetings Committee
      • AIRR Community Working Groups & Sub-Committees
    • Sponsors & Partners
  • Society meetings
    • Computational Antibody Discovery: State of the Art
      • Computational Antibody Discovery Symposium Participants
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2024
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 10 – 12 June, 2025 | Congress Center, Basel Switzerland.
      • Scientific Advisors, Antibody Engineering & Therapeutics Europe
    • FOCIS Symposia
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2025 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2024 James S. Huston Antibody Science Talent Award Recipient
      • 2023 James S. Huston Antibody Science Talent Award Recipient
      • 2022 James S. Huston Antibody Science Talent Award Recipient
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • Huston Award submission guidelines
    • Research Competitions
      • Research Competition Winners
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
      • Imaging Calendar Competition winners
        • The Antibody Society 2025 Calendar
        • The Antibody Society 2024 Calendar
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings in 2025
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody News Podcast
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars in 2025
    • The Antibody Series Lectures
    • Antibody Discovery & Development
    • Adaptive Immune Receptor Repertoires
    • Antibodies to Watch
    • Commercializing Antibody Therapeutics
    • Antibody Validation
      • 4th International Antibody Validation Meeting, Sep 2023
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
You are here: Home / Antibody News You Should Know

Antibody News You Should Know

Antibody-based therapeutics are advancing in clinical development at a rapid rate and being approved in record numbers.

To keep our members up to date on recent events, we compile relevant information from news releases and other sources, and send this “Antibody News You Should Know” to our members via email twice per month. We include news about:

  • Clinical studies started recently, focusing on the first Phase 1, Phase 2 or Phase 3 study
  • Submission of marketing applications
  • Marketing approvals
  • Financing, collaborations and licensing deals
  • Regulatory agency designations granted (e.g., Orphan Drug, PRIME, Breakthrough Therapy, Priority review)

If you are not a Society member, please register to receive Antibody News delivered twice a month by email.

No time to read the whole newsletter? Try listening to it! Subscribe to our 10-minute Antibody News podcast.

Note: From March 15, 2020 to July 1, 2022, we included in-depth coverage of news related to COVID-19 biologic interventions.

As a service to the community, The Antibody Society offers past “Antibody News You Should Know”, which can be accessed via links below. The PDFs include links to the original source and can be searched by keywords (e.g., SARS-CoV-2, bispecific, antibody-drug conjugate).


2024 Antibody News You Should Know

View PDF of Antibody News from Q2 2024 (Apr-Jun)


2024 Antibody News You Should Know

View PDF of Antibody News from Q1 2024 (Jan-Mar)


2023 Antibody News You Should Know

View PDF of Antibody News from Q2, Q3, and Q4 2023 (Apr-Dec)

View PDF of Antibody News from Q1 2023 (Jan-Mar)


2022 Antibody News You Should Know

View PDF of Antibody News from Q4 2022 Oct-Dec)

View PDF of Antibody News from Q3 2022 (Jul-Sep)

View PDF of Antibody News from Q2 2022 (Apr-Jun)

View PDF of Antibody News from Q1 2022 (Jan-Mar)


2021 Antibody News You Should Know

View PDF of Antibody News from Q4 2021 (Oct-Dec)

View PDF of Antibody News from Q3 2021 (Jul-Sep)

View PDF of Antibody News from Q2 2021 (Apr-Jun)

View PDF of Antibody News from Q1 2021 (Jan-Mar)


2020 Antibody News You Should Know

View PDF of Antibody News from H2 2020 (Jul-Dec)

View PDF of Antibody News from Q2 2020 (Apr-Jun)

View PDF of Antibody News from Q1 2020 (Jan-Mar)


2019 Antibody News You Should Know

View PDF of Antibody News from Apr 15-Dec 31, 2019

  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals